Syndax scored the first menin approval, but Kura is first with a licensing deal.

GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.

A CD22-directed Car that has had several owners will next year deliver its most important dataset.

The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.

A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.

NXP800 yields neither severe thrombocytopenia, nor any responses.

For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.